Marine organisms as a source of new anticancer agents

Mans, 2000, Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds, Oncologist, 5, 185, 10.1634/theoncologist.5-3-185 Cragg, 1997, Natural products in drug discovery and development, J Nat Prod, 60, 52, 10.1021/np9604893 Schwartsmann, 1993, Anticancer drug screening and discovery in the 29s: a European perspective, Eur J Cancer, 3, 10.1016/0959-8049(93)90567-Y Schwartsmann, 2000, Marine organisms and other novel natural sources of new cancer drugs, Ann Oncol, 11, 235, 10.1093/annonc/11.suppl_3.235 Cragg, 1999, Discovery and development of antineoplastic agents from natural sources, Cancer Invest, 17, 153, 10.1080/07357909909011730 Cragg, 1997, Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents, Semin Oncol, 24, 156 Pomponi, 1999, The bioprocess-technological potential of the sea, J Biotechnol, 70, 5, 10.1016/S0168-1656(99)00053-X Schweitzer, 1991, Summary of the workshop on drug development, biologic diversity, and economic growth, J Natl Cancer Inst, 83, 1294, 10.1093/jnci/83.18.1294 Rinehart, 2000, Antitumor compounds from tunicates, Med Res Rev, 20, 1, 10.1002/(SICI)1098-1128(200001)20:1<1::AID-MED1>3.0.CO;2-A Geldof, 1999, Cytotoxicity and neurocytoxicity of new marine anticancer agents evaluated using in vitro assays, Cancer Chemother Pharmacol, 44, 312, 10.1007/s002800050983 Shin, 1991, Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose-limiting, Cancer Chemother Pharmacol, 29, 145, 10.1007/BF00687325 Weiss, 1994, A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study, Invest New Drugs, 12, 41, 10.1007/BF00873234 Urdiales, 1996, Antiproliferative effect of dehydrodidemin B (DDB), a depsipeptide isolated from Mediterraneam tunicates, Cancer Lett, 102, 31, 10.1016/0304-3835(96)04151-1 Raymond, 2000, Phase I and pharmacokinetic study of aplydine, a marine derived compound, given as a 24h infusion every 2 weeks in patients with advanced solid tumors and non-Hodgkin's lymphoma, Ann Oncol, 11, 134 Izquierdo, 2000, A phase I study of aplidine, a marine derived compound, given as a 1h infusion weekly × 3 in advanced solid tumors and non-Hodgkin's lymphomas, Ann Oncol, 11, 134 Maroun, 2000, Phase I study of aplidine in a 1 hour daily infusion × 5 q 3 weeks in patients with solid tumors and low and intermediate grade non-Hodgkin's lymphomas: A National Cancer Institute of Canada-Clinical Trials Group study, Ann Oncol, 11, 136 Garcia-Rocha, 1996, Characterisation of antimitotic products from marine organisms that disorganize the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15, Br J Cancer, 73, 875, 10.1038/bjc.1996.176 Zewails-Foote, 1999, Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove, J Med Chem, 42, 2493, 10.1021/jm990241l Minuzzo, 2000, Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743, Proc Natl Acad Sci USA, 12, 6780, 10.1073/pnas.97.12.6780 Demetri, 2000, Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials, Ann Oncol, 11, 126 Le Cesne, 2000, Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: a STBSG-EORTC trial, Ann Oncol, 11, 126 Demetri, 2000, Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 US-based phase II trials, Proc Am Soc Clin Oncol, 19, 553 Le Cesne, 2000, Phase II study of ET-743 in advanced soft tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial, Proc Eur SocMed Oncol, 126 Zelek L, Yovine A, Brain E, et al. Preliminary results of phase II study of Ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3 weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts). Proceedings of the NCI-EORTC-AACR conference. Amsterdam, November 7–10, 2000: 85 (Abstr 212). Zelek L, Yovine A, Brain E, et al. Preliminary results of phase II study of Ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3 weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts). Proceedings of the NCI-EORTC-AACR conference. Amsterdam, November 7–10, 2000: 85 (Abstr 212). Delaloge, 2001, Ecteinascidin-743: a marine derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity, J Clin Oncol, 19, 1248, 10.1200/JCO.2001.19.5.1248 Poncet, 1999, The dolastatins, a family of promising antineoplastic agents, Curr Pharm Des, 5, 139, 10.2174/1381612805666230109214008 Bai, 1990, Dolastatin 10, a powerful cytostatic pep tide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain, Biochem Pharmacol, 39, 1941, 10.1016/0006-2952(90)90613-P Pathak, 1998, Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line, Oncol Rep, 5, 373 Wright, 1999, Clinical trials referral resource. Clinical trials of dolastatin-10, Oncology, 3, 68 Pitot, 1999, Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, Clin Cancer Res, 5, 525 Madden, 2000, Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors, Clin Cancer Res, 6, 1293 Krug, 2000, Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer, Ann Oncol, 11, 227, 10.1023/A:1008349209956 Wender, 1999, The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues, Med Res Rev, 19, 388, 10.1002/(SICI)1098-1128(199909)19:5<388::AID-MED6>3.0.CO;2-H Pettit, 1982, Isolation and structure of bryostatin-1, J Am Chem Soc, 104, 6846, 10.1021/ja00388a092 Trenn, 1988, Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins, J Immunol, 140, 433, 10.4049/jimmunol.140.2.433 Hornung, 1992, Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro and in vivo activity, Cancer Res, 52, 101 Varterasian, 1998, Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia, J Clin Oncol, 16, 56, 10.1200/JCO.1998.16.1.56 Jayson, 1995, A phase I trial of bryostatin 1 in patients with advanced malignancies using a 24 hour intravenous infusion, Br J Cancer, 72, 461, 10.1038/bjc.1995.356 Prendiville, 1993, A phase I study of intravenous bryostatin 1 in patients with advanced cancer, Br J Cancer, 68, 418, 10.1038/bjc.1993.352 Propper, 1998, A phase II study of bryostatin 1 in metastatic malignant melanoma, Br J Cancer, 78, 1337, 10.1038/bjc.1998.680 Ahmad, 2000, Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2–chlorodeoxyadenoside: case report, Clin Cancer Res, 6, 1328 Moore, 1996, Cyclic peptides and depsipeptides from cyanobacteria: a review, J Ind Microbiol, 16, 134, 10.1007/BF01570074 Ueda, 1994, Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 on Ha-ras transformed NIH3T3 cells, Biosci Biotech Biochem, 58, 1579, 10.1271/bbb.58.1579 Nakajima, 1998, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp Cell Res, 241, 126, 10.1006/excr.1998.4027 Ueda, 1994, FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Antitumor activities on experimental tumors in mice, J Antibiot (Tokyo), 47, 315, 10.7164/antibiotics.47.315 Kowalsky, 1997, The micro tubule-stabilising agent discodermolide competitively inhibits the binding of paclitaxel to tubulin polymers, enhances tubuline nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells, Mol Pharmacol, 52, 613, 10.1124/mol.52.4.613 ten Harr, 1996, Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol, Biochem, 35, 243, 10.1021/bi9515127 Kitagawa, 1990, Antitumor marine natural products, Gan To Kagaku Ryoho, 17, 322 Berlinck, 1998, Granulatimide, isogranulatimide and didemnimide E, aromatic alkaloids isolated from the Brazilian ascidian didemnum granulatum: structure elucidation, synthesis and G2 checkpoint inhibition activity, J Org Chem, 63, 9850, 10.1021/jo981607p Casapullo, 2000, New bisindole alkaloids of the topsentin and hamacanthin classes from the Mediterranean marine sponge. Rhaphisia lacazei, J Nat Prod, 63, 447, 10.1021/np9903292 Chen, 1999, Bioactive sesquiterpenes from a Taiwanese marine sponge. Parahigginsia sp, J Nat Prod, 62, 573, 10.1021/np980491p Matsumoto, 1999, Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction, Anticancer Drugs, 10, 39, 10.1097/00001813-199901000-00006 Rein, 1999, Polyketides from dinoflagellates: origins, pharmacology and biosynthesis, Comp Biochem Physiol B Biochem Mol Biol, 124, 117, 10.1016/S0305-0491(99)00107-8 McDaniel, 1995, Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic units, Nature, 375, 549, 10.1038/375549a0 Kan, 1999, A new cyclic depsipeptide from the hawaiian green alga bryopsis species, J Nat Prod, 62, 1169, 10.1021/np990053y Menon, 2000, Antitumor activity of cryptophycins: effect of infusion time and combination studies, Cancer Chemother Pharmacol, 46, 142, 10.1007/s002800000135 Christian, 1997, Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute, Semin Oncol, 24, 219